Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 5/20 | 0.33 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300799 | 0.89 | PARP1 (0.35) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL2361634 | 0.78 | PARP1 (0.33) | KDM4EALDH1A1MAPTHSD17B10ALOX15 | |
| SCHEMBL30054908 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL22702928 | 0.75 | KDM4E (0.39) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4947364 | 0.75 | PARP1 (0.36) | KDM4EALDH1A1MAPTHSD17B10ALOX15 | |
| SCHEMBL10909321 | 0.75 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTHSD17B10ALOX15 | |
| SCHEMBL30056728 | 0.75 | FABP6 (0.40) | ALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL23846769 | 0.75 | FABP6 (0.40) | ALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL30841789 | 0.73 | PARP1 (0.33) | PARP1 | |
| SCHEMBL30054287 | 0.72 | MEN1 (0.44) | ALDH1A1MAPTHPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4121409-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298165-A | Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11407712-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α | ARCUS BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
| US-11407712-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α | HIF1AN, HIF1A, EGLN2 | KDM4E 1108/4885ALDH1A1 2257/4885MAPT 2738/4885 |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | KDM4E 1072/4885ALDH1A1 2241/4885MAPT 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.